A Case of Acute Interstitial Nephritis After Two Doses of the BNT162b2 SARS-CoV-2 Vaccine

References

• Patel C, Shah HH. Vaccine-associated kidney diseases: a narrative review of the literature. Saudi J Kidney Dis Transpl. 2019;30(5):1002–1009. PMID: 31696837. doi:10.4103/1319-2442.270254
   Web of Science ®Google Scholar
• Mancianti N, Guarnieri A, Tripodi S, Salvo DP, Garosi G. Minimal change disease following vaccination for SARS-CoV-2. J Nephrol. 2021;34:1–2. doi:10.1007/s40620-021-01091-1
   Web of Science ®Google Scholar
• Komaba H, Wada T, Fukagawa M. Relapse of minimal change disease following the Pfizer-BioNTech COVID-19 vaccine. Am J Kidney Dis. 2021;78(3):469–470. doi:10.1053/j.ajkd.2021.05.006
   PubMed Web of Science ®Google Scholar
• Lebedev L, Sapojnikov M, Wechsler A, et al. Minimal change disease following the Pfizer-BioNTech COVID-19 vaccine. Am J Kidney Dis. 2021;78(1):142–145. doi:10.1053/j.ajkd.2021.03.010
   PubMed Web of Science ®Google Scholar
• Weijers J, Alvarez C, Hermans MMH. Post-vaccinal minimal change disease. Kidney Int. 2021;100(2):459–461. doi:10.1016/j.kint.2021.06.004
   Web of Science ®Google Scholar
• Leclerc S, Royal V, Lamarche C, Laurin LP. Minimal change disease with severe acute kidney injury following the Oxford-AstraZeneca COVID-19 vaccine: a case report. Am J Kidney Dis. 2021;78(4):607–610. PMID: 34242687; PMCID: PMC8260495. doi:10.1053/j.ajkd.2021.06.008
   PubMed Web of Science ®Google Scholar
• Anderegg MA, Liu M, Saganas C, et al. De novo vasculitis after mRNA-1273 (Moderna) vaccination. Kidney Int. 2021;100(2):474–476. doi:10.1016/j.kint.2021.05.016
   PubMed Web of Science ®Google Scholar
• Bomback AS, Kudose S, D’Agati VD. De Novo and relapsing glomerular diseases after COVID-19 vaccination: what do we know so far? Am J Kidney Dis. 2021;78(4):477–480. doi:10.1053/j.ajkd.2021.06.004
   PubMed Web of Science ®Google Scholar
• Klomjit N, Alexander MP, Fervenza FC, et al. COVID-19 vaccination and glomerulonephritis. Kidney Int Rep. 2021. PMID: 34632166; PMCID: PMC8493782. doi:10.1016/j.ekir.2021.09.008
   Web of Science ®Google Scholar
• Johansen JD, Aalto-Korte K, Agner T, et al. European society of contact dermatitis guideline for diagnostic patch testing - recommendations on best practice. Contact Dermatitis. 2015;73(4):195–221. doi:10.1111/cod.12432
   PubMed Web of Science ®Google Scholar
• Ebo DG, Bridts CH, Mertens CH, Sabato V. Principles, potential, and limitations of ex vivo basophil activation by flow cytometry in allergology: a narrative review. J Allergy Clin Immunol. 2021;147(4):1143–1153. doi:10.1016/j.jaci.2020.10.027
   PubMed Web of Science ®Google Scholar
• Kano Y, Hirahara K, Mitsuyama Y, Takahashi R, Shiohara T. Utility of the lymphocyte transformation test in the diagnosis of drug sensitivity: dependence on its timing and the type of drug eruption. Allergy. 2007;62(12):1439–1444. doi:10.1111/j.1398-9995.2007.01553.x
   PubMed Web of Science ®Google Scholar
• Pichler WJ, Tilch J. The lymphocyte transformation test in the diagnosis of drug hypersensitivity. Allergy. 2004;59(8):809–820. doi:10.1111/j.13989995.2004.00547.x
   PubMed Web of Science ®Google Scholar
• Kawamata M, Akimoto T, Sugase T, et al. Tubulointerstitial nephritis and uveitis syndrome: are drugs offenders or bystanders? Clin Med Insights Case Rep. 2016;9:21–24. doi:10.4137/CCRep.S36862
   Google Scholar
• Fujii T, Kawasoe K, Nishizawa Y, et al. A suspected case of drug-induced tubulointerstitial nephritis by pilocarpine hydrochloride. CEN Case Rep. 2019;8:246–251. doi:10.1007/s13730-019-00401-8
   Web of Science ®Google Scholar
• Koda R, Watanabe H, Tsuchida M, et al. Immune checkpoint inhibitor (nivolumab)-associated kidney injury and the importance of recognizing concomitant medications known to cause acute tubulointerstitial nephritis: a case report. BMC Nephrol. 2018;19(48). doi:10.1186/s12882-018-0848-y
   Web of Science ®Google Scholar
• Shima H, Okamoto T, Tashiro M, et al. Alogliptin-induced minimal change nephrotic syndrome and interstitial nephritis. Kidney Med. 2019;1(2):75–78. doi:10.1016/j.xkme.2019.03.001
   Google Scholar
• Watad A, De Marco G, Mahajna H, et al. Immune-mediated disease flares or new-onset disease in 27 subjects following mRNA/DNA SARS-CoV-2 vaccination. Vaccines. 2021;9(5):435. doi:10.3390/vaccines9050435
   PubMed Web of Science ®Google Scholar
• Rajan TV. The Gell-Coombs classification of hypersensitivity reactions: a re-interpretation. Trends Immunol. 2003;24(7):376–379. doi:10.1016/s1471-4906(03)00142-x
   PubMed Web of Science ®Google Scholar
• Segal Y, Shoenfeld Y. Vaccine-induced autoimmunity: the role of molecular mimicry and immune crossreaction. Cell Mol Immunol. 2018;15(6):586–594. doi:10.1038/cmi.2017.151
   PubMed Web of Science ®Google Scholar
• Caso F, Costa L, Ruscitti P, et al. Could Sars-coronavirus-2 trigger autoimmune and/or autoinflammatory mechanisms in genetically predisposed subjects? Autoimmun Rev. 2020;19:102524. doi:10.1016/j.autrev.2020.102524
   PubMed Web of Science ®Google Scholar
• Sette A, Crotty S. Adaptive immunity to SARS-CoV-2 and COVID-19. Cell. 2021;184(4):861–880. doi:10.1016/j.cell.2021.01.007
   PubMed Web of Science ®Google Scholar
• Kalimuddin S, Tham CYL, Qui M, et al. Early T cell and binding antibody responses are associated with COVID-19 RNA vaccine efficacy onset. Med. 2021;2(6):682–688.e4. doi:10.1016/j.medj.2021.04.003
   PubMed Web of Science ®Google Scholar
• Carvalho JC, Cunha F, Coutinho IA, Loureiro C, Faría E, Todo Bom A. Hypersensitivity reactions to vaccines: current evidence and standards for SARS-CoV-2 vaccines. Acta Med Port. 2021;34(7–8):541. doi:10.20344/amp.16096
   Web of Science ®Google Scholar
• Aydın MF, Yıldız A, Oruç A, et al. Relapse of primary membranous nephropathy after inactivated SARS-CoV-2 virus vaccination. Kidney Int. 2021;100:464–465. doi:10.1016/j.kint.2021.05.001
   PubMed Web of Science ®Google Scholar
• Masset C, Kervella D, Kandel-Aznar C, Fantou A, Blancho G, Hamidou M. Relapse of IgG4-related nephritis following mRNA COVID-19 vaccine. Kidney Int. 2021;100(2):465–466. doi:10.1016/j.kint.2021.06.002
   PubMed Web of Science ®Google Scholar
• Kervella D, Jacquemont L, Chapelet-Debout A, et al. Minimal change disease relapse following SARS-CoV2 mRNA vaccine. Kidney Int. 2021;100:457–458. doi:10.1016/j.kint.2021.04.033
   Web of Science ®Google Scholar
• Koenig HC, Sutherland A, Izurieta HS, McGonagle D. Application of the immunological disease continuum to study autoimmune and other inflammatory events after vaccination. Vaccine. 2011;29:(5)913–919. doi:10.1016/j.vaccine.2010.10.044
   Web of Science ®Google Scholar